INT336123

Context Info Confidence 0.44 First Reported 2010 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 0.20 Pain Relevance 0.04

Pain Term Frequency Confidence Heat Bioavailability 2 72.32 cytokine 1 5.00 fibrosis 3 5.00 withdrawal 3 5.00 Inflammation 3 5.00 ischemia 2 5.00 agonist 1 5.00 imagery 1 5.00 headache 1 5.00 antagonist 1 5.00

Disease Term Frequency Confidence Heat Diabetes Mellitus 23 99.64 Disease 2 98.64 Hypertension 34 50.00 Fibrosis 2 5.00 Death 3 5.00 Necrosis 2 5.00 Adhesions 2 5.00 Metabolic Syndrome 4 5.00 Obesity 10 5.00 Atherosclerotic Plaque 1 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Pharmacokinetic studies have shown that there is no need for dose adjustment in patients with renal or hepatic disease or for elderly patients or patients with diabetes.11,12 Due to its lack of effect on cytochrome P450 isoenzyme activities, aliskiren has a low potential for drug interactions.9 Effects of aliskiren on RAS components

Regulation (lack) of Gene_expression (activities) of cytochrome P450 isoenzyme associated with diabetes mellitus and disease

1) Confidence 0.44 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952455 Disease Relevance 0.20 Pain Relevance 0.04

General Comments

This test has worked.